OnePeptideShip

Retatrutide Research Profile

Research Use

Retatrutide is a novel triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. In Phase 2 trials, it produced over 24% body weight reduction - the highest recorded for any injectable weight loss agent.

Retatrutide Quick Technical Specifications

Category
Triple Agonist Research
Elimination Half-Life
approx. 6 days (140 hours)
Storage Protocol
Refrigerated (2°C-8°C)
Status
Research Use
OE
Written by OnePeptideShip Editorial Team
Reviewed by Dr. Aris Thorne, MD, Board Certified Endocrinology Advisor
Updated September 2026

Mechanism of Action & Biochemical Context

Retatrutide is a novel triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. In Phase 2 trials, it produced over 24% body weight reduction - the highest recorded for any injectable weight loss agent.

Storage, Reconstitution & Stability Guidelines

Prior to reconstitution, lyophilized Retatrutide powder should be stored away from light between 2°C and 8°C for short-term access, or -20°C for long-term preservation. Once reconstituted with Bacteriostatic Water (0.9% benzyl alcohol preservative), maintain strict refrigeration between 2°C and 8°C. Do not freeze liquid solution.

Cited Scientific References

  1. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023.

Calculate Retatrutide Syringe Units

Input your vial mg and BAC water mL to calculate exact U-100 draw units.

Open Retatrutide Calculator →

Frequently Asked Questions

Based on Phase 2 trial protocols, the standard escalation is: 2.0mg (Weeks 1-4) → 4.0mg (Weeks 5-8) → 6.0mg (Weeks 9-12) → 9.0mg (Weeks 13-16) → 12.0mg (Week 17+). Each step must be held for a full 4 weeks minimum. The maximum clinical trial dose was 12.0mg once weekly.

Add 2mL of Bacteriostatic Water to the 10mg vial. This gives a concentration of 5mg/mL. For a 2.0mg dose, draw 0.4mL, which is exactly 40 units on a U-100 syringe. The calculator above will compute this automatically.

Glucagon's primary role is raising blood sugar by signaling the liver to release glucose. However, it also dramatically raises basal energy expenditure (metabolic rate) and drives lipolysis (fat breakdown) in the liver. When combined with GLP-1 and GIP (which keep insulin in balance to prevent blood sugar spikes), the glucagon effect becomes purely a powerful fat-burning and metabolism-elevating signal.

No, as of 2024-2025, Retatrutide is in Phase 3 clinical trials (the TRIUMPH trial series). It is strictly a research compound and is not approved for human therapeutic use. It should only be handled in proper research settings.

Retatrutide has produced significantly greater weight loss in Phase 2 trials - approximately 24.2% body weight reduction at the 12mg dose over 48 weeks, compared to Tirzepatide's ~22% at 15mg. The key differentiator is glucagon agonism, which increases resting metabolic rate, a mechanism completely absent in Tirzepatide.

Yes. Glucagon receptor agonism is known to moderately increase resting heart rate. In clinical trials, subjects on Retatrutide showed a mean increase of 2-5 bpm in resting heart rate. Researchers must monitor for tachycardia, especially during the first 4-8 weeks of escalation.

Research chemical suppliers typically offer Retatrutide in 5mg, 10mg, 20mg, and 30mg vials. For the full 12mg maximum dose, you would need to draw from a vial with at least 12mg of peptide, or use multiple smaller vials. The 20mg or 30mg vials are most practical for subjects at the higher end of the titration schedule.